Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free
factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

From the 1940s through 2010, warfarin (Coumadin, Bristol-Myers Squibb) was the only oral
anticoagulant on the market in the US for the treatment and prevention of thromboembolic …

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers
Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders …

Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for
patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …